Livzon Pharmaceutical Group Inc. (SZSE:000513) Stock Most Popular Amongst Public Companies Who Own 44%, While Individual Investors Hold 38%
Livzon Pharmaceutical Group Inc. (SZSE:000513) Stock Most Popular Amongst Public Companies Who Own 44%, While Individual Investors Hold 38%
Key Insights
关键见解
- Livzon Pharmaceutical Group's significant public companies ownership suggests that the key decisions are influenced by shareholders from the larger public
- The top 8 shareholders own 50% of the company
- Institutions own 15% of Livzon Pharmaceutical Group
- 丽珠制药集团拥有大量上市公司所有权,这表明关键决策受广大公众股东的影响
- 前 8 名股东拥有公司 50% 的股份
- 机构拥有丽珠制药集团15%的股份
Every investor in Livzon Pharmaceutical Group Inc. (SZSE:000513) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are public companies with 44% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
丽珠制药集团有限公司(SZSE: 000513)的每位投资者都应该了解最强大的股东群体。而持有最大份额的集团是拥有44%所有权的上市公司。换句话说,该集团将从对公司的投资中获得最多(或损失最大)。
And individual investors on the other hand have a 38% ownership in the company.
另一方面,个人投资者拥有该公司38%的所有权。
In the chart below, we zoom in on the different ownership groups of Livzon Pharmaceutical Group.
在下图中,我们放大了丽珠制药集团的不同所有权群体。
What Does The Institutional Ownership Tell Us About Livzon Pharmaceutical Group?
关于丽珠制药集团,机构所有权告诉我们什么?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
机构在向自己的投资者报告时通常会根据基准来衡量自己,因此,一旦股票被纳入主要指数,他们通常会对股票更加热情。我们预计大多数公司都会有一些机构在册,尤其是在它们正在成长的情况下。
We can see that Livzon Pharmaceutical Group does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Livzon Pharmaceutical Group's earnings history below. Of course, the future is what really matters.
我们可以看到,丽珠制药集团确实有机构投资者;他们持有该公司很大一部分股票。这意味着在这些机构工作的分析师已经看过这只股票,他们很喜欢。但是就像其他人一样,他们可能错了。如果多家机构同时改变对股票的看法,你可能会看到股价快速下跌。因此,值得在下面查看丽珠制药集团的收益记录。当然,未来才是真正重要的。
We note that hedge funds don't have a meaningful investment in Livzon Pharmaceutical Group. Joincare Pharmaceutical Group Industry Co.,Ltd. is currently the largest shareholder, with 44% of shares outstanding. Guangzhou Begol Trading Corporation is the second largest shareholder owning 1.9% of common stock, and UBS Asset Management AG holds about 1.4% of the company stock.
我们注意到,对冲基金没有对丽珠制药集团进行有意义的投资。健健药业集团工业有限公司, Ltd. 目前是最大股东,已发行股份的44%。广州Begol贸易公司是第二大股东,拥有1.9%的普通股,瑞银资产管理股份公司持有该公司约1.4%的股份。
We also observed that the top 8 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.
我们还观察到,前8名股东占股票登记册的一半以上,少数规模较小的股东可以在一定程度上平衡大股东的利益。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.
虽然研究公司的机构所有权可以为您的研究增加价值,但研究分析师的建议以更深入地了解股票的预期表现也是一种好做法。有不少分析师报道了该股,因此你可以很容易地研究预测的增长。
Insider Ownership Of Livzon Pharmaceutical Group
丽珠制药集团的内部所有权
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
公司内部人员的定义可能是主观的,并且在不同的司法管辖区之间确实有所不同。我们的数据反映了个人内部人士,至少涵盖了董事会成员。管理层最终对董事会负责。但是,经理成为执行委员会成员的情况并不少见,尤其是当他们是创始人或首席执行官时。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常认为内部所有权是一件好事。但是,在某些情况下,这使其他股东更难追究董事会对决策的责任。
Our most recent data indicates that insiders own less than 1% of Livzon Pharmaceutical Group Inc.. However, it's possible that insiders might have an indirect interest through a more complex structure. It's a big company, so even a small proportional interest can create alignment between the board and shareholders. In this case insiders own CN¥121m worth of shares. Arguably, recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling.
我们的最新数据显示,内部人士拥有丽珠制药集团不到1%的股份。但是,内部人士有可能通过更复杂的结构获得间接利益。这是一家大公司,因此即使是很小的比例权益也可以在董事会和股东之间建立一致。在本案中,内部人士拥有价值12100万元人民币的股票。可以说,最近的买入和卖出同样值得考虑。你可以点击这里查看内部人士是否在买入或卖出。
General Public Ownership
一般公有制
The general public-- including retail investors -- own 38% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
包括散户投资者在内的公众拥有该公司38%的股份,因此不容忽视。尽管这种所有权规模可能不足以影响对他们有利的政策决定,但它们仍然可以对公司政策产生集体影响。
Public Company Ownership
上市公司所有权
We can see that public companies hold 44% of the Livzon Pharmaceutical Group shares on issue. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.
我们可以看到,上市公司持有丽珠制药集团已发行股份的44%。这可能是战略利益,两家公司可能有相关的商业利益。可能是他们已经消失了。这一裁定可能值得进一步调查。
Next Steps:
后续步骤:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks for example - Livzon Pharmaceutical Group has 1 warning sign we think you should be aware of.
尽管值得考虑拥有公司的不同群体,但还有其他因素更为重要。以风险为例-丽珠制药集团有 1 个警告信号,我们认为您应该注意。
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
但归根结底,决定这家企业所有者的表现的是未来,而不是过去。因此,我们认为最好看一下这份免费报告,该报告显示了分析师是否预测了更光明的未来。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?担心内容吗?直接联系我们。或者,发送电子邮件给编辑组(网址为)simplywallst.com。
Simply Wall St 的这篇文章本质上是笼统的。我们仅使用公正的方法提供基于历史数据和分析师预测的评论,我们的文章并非旨在提供财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不会考虑最新的价格敏感型公司公告或定性材料。华尔街只是没有持有上述任何股票的头寸。